Mgc Pharmaceuticals Share Discussion Threads

[heatseek77] 16/3/2023 10:06

Cheers looney see the inbreds have started a fredz (@English classes required)

[sloppyjoe2] 08/3/2023 14:01

Seems a perfectly reasonable view. Thank you.

[looneytune] 08/3/2023 13:16

They need money 💰- can’t build a business without it. If you can’t pay staff you can’t do trials, no trials equals no business. This is a long term hold. At least Mercer are prepare to offer funds albeit in return for a piece of the action. They assume there will be action so no reason why we should think any differently. Just my opinion.

[sloppyjoe2] 08/3/2023 13:07

No comments on today's RNS?

[looneytune] 06/3/2023 23:35

More good news:-

7 March 2023 ASX Code: MXC LSE Code: MXC
Completion of CimetrATM Mechanism of Action study
Key Highlights:
• •
•
• •
TM’s ability
MGC Pharma has completed an in-vitro pre-clinical study on CimetrATM’s mechanism of
action (MoA)
The study, which was carried out at the GLP-Certified Science in Action Lab, in Ness Ziona,
Israel, examined the mechanism underlying the CimetrATM-mediated anti-inflammatory
effect on human Peripheral Blood Mononuclear Cells (PBMC)
The study demonstrated the inhibitory effect of CimetrATM on the mRNA expression and,
as a result, on the secretion of IL-32 proteins and the subsequent suppression of
inflammation and inflammatory cytokines
Additional findings show that CimetrATM increases intracellular HO-1 the antioxidant
activity in cells, protecting against oxidative stress that causes the inflammation
Further demonstrates CimetrA
to be extended into the anti-inflammatory
market
MGC Pharmaceuticals Ltd (‘MGC Pharma’ or ‘the Company’) a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has completed the pre-clinical study on CimetrATM, exploring the Mechanism of Action (MoA) of the product.
The study was conducted on human Peripheral Blood Mononuclear Cells (PBMC) crucial in the immune response, the results of which are consistent with previous reports. The administration of CimetrATM before and during Lipopolysaccharide (LPS) stimulation to produce an immune response and induce cytokine generation, resulted in a significant decrease in IL-32 mRNA expression and a resulting decrease in inflammation.
As such, we conclude that the presence of the IL-32 mRNA protein plays a critical role in the secretion of the cytokines (Figure 1), such as tumour necrosis factor-alpha (TNF-α) and IL-6 (Figure 2), that cause inflammation. Control of this protein is then the fundamental pathway to manage and reduce inflammation. The preclinical study demonstrates that the Mechanism of Action in MGC’s core development product, CimetrATM is the suppression of IL-32 protein via effect on the mRNA expression. The graph below demonstrates the decreased (up to undetectable values) IL-32A level after the treatment of the PBMC induced tissue with CimetrA in comparison with the baseline (LPS column), Placebo treatment and not treated control.

Link to article

[samsung2020] 02/3/2023 21:32

Hi mate and all. I generally check in every few days and will remove any thrash when get chance.Hope all are well. I continue to build my pot here, it's a long term stock.Ta, Sam.

[flc] 02/3/2023 21:14

Keep up the good Samsung..you know its going up..you make me smile.

[sloppyjoe2] 02/3/2023 20:08

Go away, you vile cretin.

[flc] 02/3/2023 16:31

Not really Kenbos but just happy to be patient and see what happens.

[sloppyjoe2] 01/3/2023 14:04

Just dipped a toe with £1k (204k shares)...